The company finalized the sale of nearly 10.6 million shares late Thursday, marking a significant increase from its initial target of 9.4 million. By opting for a higher volume of shares at the $16 price point, Bambusa navigated a range that previously spanned from $15 to $17 per share. Investors will be able to track the stock under the ticker symbol BBTX starting with the opening bell.
Bambusa Therapeutics Raises $169 Million in Upsized Nasdaq Debut
Boston-based clinical-stage biopharmaceutical firm Bambusa Therapeutics is hitting the Nasdaq Global Select Market this Friday following an upsized initial public offering. The company successfully priced its shares at $16, landing squarely at the midpoint of its projected range while securing $169 million in fresh capital for its pipeline.
When reusing this material a link to Money Talk is required.
Comments (0)
No comments yet. Be the first!